Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study - Irwin, D. E.; Milsom, I.; Hunskaar, S.; Reilly, K.; Kopp, Z.; Herschorn, S.; Coyne, K.; Kelleher, C.; Hampel, C.; Artibani, W. (Eur Urol, 2006)

The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study - Coyne, K. S.; Sexton, C. C.; Thompson, C. L.; Milsom, I.; Irwin, D.; Kopp, Z. S.; Chapple, C. R.; Kaplan, S.; Tubaro, A.; Aiyer, L. P. (BJU Int, 2009)

Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries - Li, M. K.; Garcia, L. A.; Rosen, R. (BJU Int, 2005)

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? - Kramer, G.; Mitteregger, D.; Marberger, M. (Eur Urol, 2007)

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction - Uckert, S.; Oelke, M. (Br J Clin Pharmacol, 2011)

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia - Cantrell, M. A.; Baye, J.; Vouri, S. M. (Pharmacotherapy, 2013)

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia - Homma, Y.; Gotoh, M.; AKawauchi, A.; Kojima, Y.; Maeda, K.; Masumori, N.; Nagai, A.; Saitoh, T.; Sakai, H.; Takahashi, S. (RichHill Medical Inc., 2017)

European Association of U: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction - Oelke, M.; Bachmann, A.; Descazeaud, A.; Emberton, M.; Gravas, S.; Michel, M. C.; N’Dow, J.; Nordling, J.; Rosette, J. J. (Eur Urol, 2013)

The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia - Giuliano, F.; Uckert, S.; Maggi, M.; Birder, L.; Kissel, J.; Viktrup, L. (Eur Urol, 2013)

Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats - Morelli, A.; Sarchielli, E.; Comeglio, P.; Filippi, S.; Mancina, R.; Gacci, M.; Vignozzi, L.; Carini, M.; Vannelli, G. B.; Maggi, M. (J Sex Med, 2011)

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit - Morelli, A.; Comeglio, P.; Filippi, S.; Sarchielli, E.; Vignozzi, L.; Maneschi, E.; Cellai, I.; Gacci, M.; Lenzi, A.; Vannelli, G. B. (Prostate, 2013)

Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: attenuation of chronic pelvic pain by repeated administration of tadalafil - Yamaguchi, H.; Kurita, M.; Okamoto, K.; Kotera, T.; Oka, M. (Prostate, 2019)

Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats - Kamijo, T.; Sato, S.; Kitamura, T. (Prostate, 2001)

Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis - Tsunemori, H.; Sugimoto, M.; Xia, Z.; Taoka, R.; Oka, M.; Kakehi, Y. (Urology, 2011)

Effect of a phytotherapeutic agent, Eviprostat (R), on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis - Sugimoto, M.; Oka, M.; Tsunemori, H.; Yamashita, M.; Kakehi, Y. (Prostate, 2011)

The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate - Shibuya, S.; Xia, Z.; Sugimoto, M.; Ueda, N.; Haba, R.; Kakehi, Y. (Urology, 2014)

IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis - Nadler, R. B.; Koch, A. E.; Calhoun, E. A.; Campbell, P. L.; Pruden, D. L.; Bennett, C. L.; Yarnold, P. R.; Schaeffer, A. (J Urol, 2000)

Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia - Liu, L.; Li, Q.; Han, P.; Li, X.; Zeng, H.; Zhu, Y.; Wei, Q. (Urology, 2009)

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS - Vignozzi, L.; Gacci, M.; Cellai, I.; Morelli, A.; Maneschi, E.; Comeglio, P.; Santi, R.; Filippi, S.; Sebastianelli, A.; Nesi, G. (Prostate, 2013)

Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia - Zarifpour, M.; Nomiya, M.; Sawada, N.; Andersson, K. E. (Prostate, 2015)

Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis - Okamoto, K.; Kurita, M.; Yamaguchi, H.; Numakura, Y.; Oka, M. (Prostate, 2018)

Latest evidence on the use of Phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia - Gacci, M.; Andersson, K. E.; Chapple, C.; Maggi, M.; Mirone, V.; Oelke, M.; Porst, H.; Roehrborn, C.; Stief, C.; Giuliano, F. (Eur Urol, 2016)

Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia - Nomiya, M.; Burmeister, D. M.; Sawada, N.; Campeau, L.; Zarifpour, M.; Keys, T.; Peyton, C.; Yamaguchi, O.; Andersson, K. E. (J Urol, 2013)

Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction - Kawai, Y.; Oka, M.; Yoshinaga, R.; Fuchikami, C.; Oyama, T. (Neurourol Urodyn, 2016)

Comparison of the effects of Tadalafil and α1-Adrenoceptor antagonists on spontaneous seminal emission and electrical field stimulation-induced seminal vesicle contraction in rats - Yoshinaga, R.; Fukui, T.; Yoshifuji, M.; Fujimura, M.; Oyama, T.; Oka, M. (J Sex Med, 2019)